Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind Phase 3 Study to Compare the Immunogenicity of Clinical Trial Material of an Ad26.RSV.preF-based Vaccine for Phase 3 With Clinical Trial Material Representative of Phase 2b in Adults Aged 60 to 75 Years
Conditions
Interventions
Ad26.RSV.preF-based vaccine
Locations
9
United States
Artemis Institute for Clinical Research
San Diego, California, United States
Optimal Research
San Diego, California, United States
Accel Research Sites
Lakeland, Florida, United States
Optimal Research
Melbourne, Florida, United States
Pharmax Research Clinic Inc
Miami, Florida, United States
Research Institute of South Florida Inc
Miami, Florida, United States
Start Date
October 8, 2021
Primary Completion Date
March 7, 2022
Completion Date
September 22, 2022
Last Updated
May 25, 2025
NCT07177508
NCT05242432
Lead Sponsor
Janssen Vaccines & Prevention B.V.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions